| Literature DB >> 33579944 |
Hyun Mu Shin1,2,3, Gwanghun Kim4,5,6, Sangjib Kim7, Ji Hyun Sim6, Jiyeob Choi4,8, Minji Kim4,5,6, Minsuk Kwon9, Sang-Kyu Ye4,5,10,11, Dong-Sup Lee12,4,5,6,11, Seung Woo Cho13, Seung Tae Kim9, Jeeyun Lee14,15, Hang-Rae Kim16,17,18,19,20.
Abstract
Although tumor genomic profiling has identified small subsets of gastric cancer (GC) patients with clinical benefit from anti-PD-1 treatment, not all responses can be explained by tumor sequencing alone. We investigate epigenetic elements responsible for the differential response to anti-PD-1 therapy by quantitatively assessing the genome-wide chromatin accessibility of circulating CD8+ T cells in patients' peripheral blood. Using an assay for transposase-accessible chromatin using sequencing (ATAC-seq), we identify unique open regions of chromatin that significantly distinguish anti-PD-1 therapy responders from non-responders. GC patients with high chromatin openness of circulating CD8+ T cells are significantly enriched in the responder group. Concordantly, patients with high chromatin openness at specific genomic positions of their circulating CD8+ T cells demonstrate significantly better survival than those with closed chromatin. Here we reveal that epigenetic characteristics of baseline CD8+ T cells can be used to identify metastatic GC patients who may benefit from anti-PD-1 therapy.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33579944 PMCID： PMC7881150 DOI： 10.1038/s41467-021-21299-w
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919